Reporting owner · Q3 2026 · CIK 1911592

Frazier Life Sciences XI, L.P.: insider trades.

Frazier Life Sciences XI, L.P. reported 5 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 1 open-market purchase ($10.0M) and 0 sales, across 1 company.

Transactions
5
Purchases (P)
1
Sales (S)
0
Companies
1
Name as filed
Frazier Life Sciences XI, L.P.

Companies

CompanyRelationshipTransactions
Attovia Therapeutics, Inc. (ATTO)TenPercentOwner5

Transactions

5 non-derivative rows. Shares and prices as filed.
DateCompanyCodeSharesPriceOwned afterFiling
2026-08-06Attovia Therapeutics, Inc.P588,235$176,154,213Form 4
2026-08-06Attovia Therapeutics, Inc.C961,322—5,565,978Form 4
2026-08-06Attovia Therapeutics, Inc.C1,189,940—4,604,656Form 4
2026-08-06Attovia Therapeutics, Inc.C1,590,175—3,414,716Form 4
2026-08-06Attovia Therapeutics, Inc.C1,749,192—1,824,541Form 4

Questions

What stock did Frazier Life Sciences XI, L.P. buy or sell?

Frazier Life Sciences XI, L.P. reported 5 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 1 open-market purchase ($10.0M) and 0 sales, across 1 company.

Is Frazier Life Sciences XI, L.P. the same person as other filers with this name?

This page covers SEC CIK 1911592 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.

Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.

Plain-text version for agents and LLMs: /insiders/frazier-life-sciences-xi-l-p-1911592.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.